As on 27-Nov-2023 16:13 EST
$9.17
$9.15
$9.29
$8.52
2,230,656
$4.07 - 12.43
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
---|---|---|---|---|---|---|---|
Aurinia Pharmaceuticals (AUPH)
| 97.69 | 16.51 | -7.97 | 75.00 | -15.15 | 9.32 | -- |
S&P BSE Sensex*
| 8.77 | 3.75 | 1.98 | 6.23 | 14.44 | 13.26 | 12.48 |
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.90 | -6.30 | 5.30 | 2.98 | 5.53 |
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
---|---|---|---|---|---|---|---|
Aurinia Pharmaceuticals (AUPH)
| -81.11 | 65.37 | -31.74 | 197.07 | 50.22 | 115.71 | -14.98 |
S&P Small-Cap 600
| -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 | 24.74 |
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
The total asset value of Aurinia Pharmaceuticals Inc (AUPH) stood at $ 494 Mln as on 31-Mar-23
The share price of Aurinia Pharmaceuticals Inc (AUPH) is $8.54 (NASDAQ) as of 27-Nov-2023 16:13 EST. Aurinia Pharmaceuticals Inc (AUPH) has given a return of -15.15% in the last 3 years.
Aurinia Pharmaceuticals Inc (AUPH) has a market capitalisation of $ 1,320 Mln as on 23-Jun-2023. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Aurinia Pharmaceuticals Inc (AUPH) is 1.57 times as on 23-Jun-2023, a -0.38% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Aurinia Pharmaceuticals Inc (AUPH) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aurinia Pharmaceuticals Inc (AUPH) and enter the required number of quantities and click on buy to purchase the shares of Aurinia Pharmaceuticals Inc (AUPH).
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
The CEO & director of Mr. Peter S. Greenleaf M.B.A.. is Aurinia Pharmaceuticals Inc (AUPH), and CFO & Sr. VP is Mr. Joseph M. Miller CPA.
The promoters of Aurinia Pharmaceuticals Inc (AUPH) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
Company | Market Cap($ Mln) |
---|---|
104
|
|
104
|
|
83
|
|
81
|
Aurinia Pharmaceuticals Inc (AUPH) | Ratios |
---|---|
Return on equity(%)
|
-23.78
|
Return on capital employed(%)
|
--
|
Debt-to-equity ratio
|
0
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Aurinia Pharmaceuticals Inc (AUPH) was $-71 Mln.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment... of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. Read more
Sign up and get access to:
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.